128 related articles for article (PubMed ID: 37290803)
1. Predictors of sentinel lymph node metastasis in very thin invasive melanomas.
Kakish H; Sun J; Zheng DX; Ahmed FA; Elshami M; Loftus AW; Ocuin LM; Ammori JB; Hoehn RS; Bordeaux JS; Rothermel LD
Br J Dermatol; 2023 Sep; 189(4):419-426. PubMed ID: 37290803
[TBL] [Abstract][Full Text] [Related]
2. Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts.
Isaksson K; Nielsen K; Mikiver R; Nieweg OE; Scolyer RA; Thompson JF; Ingvar C
J Surg Oncol; 2018 Sep; 118(4):599-605. PubMed ID: 30196533
[TBL] [Abstract][Full Text] [Related]
3. Sentinel lymph node biopsy in acral melanoma: A Korean single-center experience with 107 patients (2006-2018).
Sohng C; Sim HB; Kim JY; Lim Y; Han MH; Lee H; Ahn BC; Huh S; Lee SJ
Asia Pac J Clin Oncol; 2021 Feb; 17(1):115-122. PubMed ID: 33079454
[TBL] [Abstract][Full Text] [Related]
4. High Mitotic Rate Predicts Sentinel Lymph Node Involvement in Thin Melanomas.
Skochdopole AJ; Kutlu OC; Engelhardt KE; Lancaster WP; Abbott AM; Camp ER
J Surg Res; 2020 Dec; 256():198-205. PubMed ID: 32711176
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration.
Walker RJB; Look Hong NJ; Moncrieff M; van Akkooi ACJ; Jost E; Nessim C; van Houdt WJ; Stahlie EHA; Seo C; Quan ML; McKinnon JG; Wright FC; Mavros MN
Ann Surg Oncol; 2022 Oct; 29(11):7010-7017. PubMed ID: 35676603
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
Han D; Zager JS; Shyr Y; Chen H; Berry LD; Iyengar S; Djulbegovic M; Weber JL; Marzban SS; Sondak VK; Messina JL; Vetto JT; White RL; Pockaj B; Mozzillo N; Charney KJ; Avisar E; Krouse R; Kashani-Sabet M; Leong SP
J Clin Oncol; 2013 Dec; 31(35):4387-93. PubMed ID: 24190111
[TBL] [Abstract][Full Text] [Related]
7. Predictors of sentinel lymph node positivity in thin melanoma using the National Cancer Database.
Conic RRZ; Ko J; Damiani G; Funchain P; Knackstedt T; Vij A; Vidimos A; Gastman BR
J Am Acad Dermatol; 2019 Feb; 80(2):441-447. PubMed ID: 30240775
[TBL] [Abstract][Full Text] [Related]
8. Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm.
Han D; Yu D; Zhao X; Marzban SS; Messina JL; Gonzalez RJ; Cruse CW; Sarnaik AA; Puleo C; Sondak VK; Zager JS
Ann Surg Oncol; 2012 Oct; 19(11):3335-42. PubMed ID: 22766986
[TBL] [Abstract][Full Text] [Related]
9. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
[TBL] [Abstract][Full Text] [Related]
10. A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas.
Wat H; Senthilselvan A; Salopek TG
J Am Acad Dermatol; 2016 Jan; 74(1):94-101. PubMed ID: 26542815
[TBL] [Abstract][Full Text] [Related]
11. Does sentinel lymph node status have prognostic significance in patients with acral lentiginous melanoma?
Pavri SN; Han G; Khan S; Han D
J Surg Oncol; 2019 Jun; 119(8):1060-1069. PubMed ID: 30883783
[TBL] [Abstract][Full Text] [Related]
12. Survival analysis and sentinel lymph node status in thin cutaneous melanoma: A multicenter observational study.
Tejera-Vaquerizo A; Ribero S; Puig S; Boada A; Paradela S; Moreno-Ramírez D; Cañueto J; de Unamuno B; Brinca A; Descalzo-Gallego MA; Osella-Abate S; Cassoni P; Carrera C; Vidal-Sicart S; Bennássar A; Rull R; Alos L; Requena C; Bolumar I; Traves V; Pla Á; Fernández-Orland A; Jaka A; Fernández-Figueres MT; Hilari JM; Giménez-Xavier P; Vieira R; Botella-Estrada R; Román-Curto C; Ferrándiz L; Iglesias-Pena N; Ferrándiz C; Malvehy J; Quaglino P; Nagore E;
Cancer Med; 2019 Aug; 8(9):4235-4244. PubMed ID: 31215168
[TBL] [Abstract][Full Text] [Related]
13. A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making.
Friedman C; Lyon M; Torphy RJ; Thieu D; Hosokawa P; Gonzalez R; Lewis KD; Medina TM; Rioth MJ; Robinson WA; Kounalakis N; McCarter MD; Gleisner AL
J Surg Oncol; 2019 Dec; 120(7):1276-1283. PubMed ID: 31602665
[TBL] [Abstract][Full Text] [Related]
14. Sentinel node biopsy improves prognostic stratification in patients with thin (pT1) melanomas and an additional risk factor.
Mitteldorf C; Bertsch HP; Jung K; Thoms KM; Schön MP; Tronnier M; Kretschmer L
Ann Surg Oncol; 2014 Jul; 21(7):2252-8. PubMed ID: 24652352
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node status affects long-term survival in patients with intermediate-thickness melanoma.
G Lben K; Berberoğlu U; Altınyollar H; Kınaş V; Turanlı S
J Cancer Res Ther; 2016; 12(2):840-4. PubMed ID: 27461661
[TBL] [Abstract][Full Text] [Related]
16. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
17. Predictors of sentinel lymph node status of cutaneous melanoma in Serbian patients.
Jokic S; Markovic I; Bukumiric Z; Jokic V; Rakovic M; Tripkovic J; Stojiljkovic D; Spurnic I; Jevric M; Matic M; Dobrosavljevic D
J BUON; 2018; 23(2):468-474. PubMed ID: 29745094
[TBL] [Abstract][Full Text] [Related]
18. The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma.
Hieken TJ; Grotz TE; Comfere NI; Inselman JW; Habermann EB
Melanoma Res; 2015 Apr; 25(2):157-63. PubMed ID: 25647736
[TBL] [Abstract][Full Text] [Related]
19. Sentinel lymph node biopsy is associated with increased cost in higher risk thin melanoma.
Aiken TJ; Stahl CC; Schwartz PB; Barrett J; Acher AW; Lemaster D; Leverson G; Weber S; Neuman H; Abbott DE
J Surg Oncol; 2021 Jan; 123(1):104-109. PubMed ID: 32939750
[TBL] [Abstract][Full Text] [Related]
20. Clark level risk stratifies patients with mitogenic thin melanomas for sentinel lymph node biopsy.
Bartlett EK; Gimotty PA; Sinnamon AJ; Wachtel H; Roses RE; Schuchter L; Xu X; Elder DE; Ming M; Elenitsas R; Guerry D; Kelz RR; Czerniecki BJ; Fraker DL; Karakousis GC
Ann Surg Oncol; 2014 Feb; 21(2):643-9. PubMed ID: 24121883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
